Rasburicase in Treating or Preventing High Levels of Uric Acid in the Blood and Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumors

This study is ongoing, but not recruiting participants.
Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Hyperuricemia
			Leukemia
			Lymphoma
			Myelodysplastic Syndromes
			Small Intestine Cancer
			Tumor Lysis Syndrome
2		Additional conditions recognized in this trial
			Duodenal Neoplasms
			Ileal Neoplasms
			Intestinal Neoplasms
			Jejunal Neoplasms
			Lymphoma, Large-Cell, Immunoblastic
			Multiple Myeloma
			Neoplasms
			Neoplasms, Plasma Cell
			Preleukemia
			Syndrome
3		More general conditions related to this trial
			Blood Protein Disorders
			Bone Marrow Diseases
			Cardiovascular Diseases
			Digestive System Diseases
			Digestive System Neoplasms
			Disease
			Duodenal Diseases
			Gastrointestinal Diseases
			Gastrointestinal Neoplasms
			Hematologic Diseases
			Hemorrhagic Disorders
			Hemostatic Disorders
			Ileal Diseases
			Immune System Diseases
			Immunoproliferative Disorders
			Intestinal Diseases
			Jejunal Diseases
			Lymphatic Diseases
			Lymphoma, Non-Hodgkin
			Lymphoproliferative Disorders
			Neoplasms by Histologic Type
			Neoplasms by Site
			Paraproteinemias
			Pathologic Processes
			Precancerous Conditions
			Vascular Diseases
4		Interventions listed in this trial
			rasburicase
5		More general drug interventions related to this trial
			Antirheumatic Agents
			Gout Suppressants
			Pharmacologic Actions
			Therapeutic Uses
6		Sponsors listed in this trial
			Prologue Research International